BENGALURU (Reuters) – Indian vaccine maker Bharat Biotech said on Friday that the Russia-Ukraine conflict had not impacted the company’s supply chains so far.
Production of Bharat Biotech’s homegrown COVID-19 vaccine Covaxin “has been fully indigenised, all (active pharmaceutical ingredients) and critical raw materials are manufactured within India,” the company said in an emailed statement.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)
